Literature DB >> 20361320

[Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy].

L Trémezaygues1, R Schmaltz, T Vogt, J Reichrath.   

Abstract

Pyoderma gangrenosum is a rare neutrophilic inflammatory skin disease, mostly observed in middle-aged adults. Etiology and pathogenesis remain unclear. Autoimmune mechanisms including immune complex-mediated neutrophilic vascular reactions have been suggested. The hallmark finding in pyoderma gangrenosum is painful ulcers with sharply circumscribed and demarcated, frequently undermined, livid borders and a necrotic base. Pyoderma gangrenosum has been described in association with a great variety of systemic disorders, ranging from inflammatory bowel diseases to myeloproliferative disorders. The diagnosis of pyoderma gangrenosum is based primarily on the clinical presentation and course. It is usually a diagnosis of exclusion. Histopathological and laboratory findings in pyoderma gangrenosum are nonspecific. The aims of therapy are the complete suppression of inflammatory disease activity, promotion of wound healing and control of pain. Frequently, successful treatment of associated diseases leads to an improvement or complete remission of pyoderma gangrenosum. Surgical interventions, including aggressive ulcer excision, recipient site preparation and autologous skin grafting have to be avoided during the active phase of the disease because the likely occurrence of pathergy inducing new lesions at surgical sites and causing a worsening the original lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20361320     DOI: 10.1007/s00105-009-1909-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  43 in total

Review 1.  Pyoderma gangrenosum: a report of 21 cases.

Authors:  Rym Benmously Mlika; Imed Riahi; Samy Fenniche; Mourad Mokni; Mohamed Raouf Dhaoui; Néjib Dess; Amel Ben Osman Dhahri; Insaf Mokhtar
Journal:  Int J Dermatol       Date:  2002-02       Impact factor: 2.736

Review 2.  Pyoderma gangrenosum.

Authors:  N M Blitz; D Rudikoff
Journal:  Mt Sinai J Med       Date:  2001 Sep-Oct

3.  Persistent purulent drainage from the glans penis: atypical presentation of pyoderma gangrenosum.

Authors:  Mark L Gonzalgo; Davi A de Lacerda; Angelo M De Marzo; David Y Chan
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

4.  Topical treatment of pyoderma gangraenosum.

Authors:  Joerg Wenzel; Rainer Gerdsen; Wolfgang Phillipp-Dormston; Thomas Bieber; Manfred Uerlich
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

5.  Superficial granulomatous pyoderma treated with intravenous immunoglobulin.

Authors:  Christopher M Dobson; Richard A Parslew; Susan Evans
Journal:  J Am Acad Dermatol       Date:  2003-03       Impact factor: 11.527

Review 6.  Treatment of pyoderma gangrenosum.

Authors:  R K Chow; V C Ho
Journal:  J Am Acad Dermatol       Date:  1996-06       Impact factor: 11.527

Review 7.  Thalidomide and its dermatologic uses.

Authors:  M Moraes; G Russo
Journal:  Am J Med Sci       Date:  2001-05       Impact factor: 2.378

Review 8.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.

Authors:  W P Daniel Su; Mark D P Davis; Roger H Weenig; Frank C Powell; Harold O Perry
Journal:  Int J Dermatol       Date:  2004-11       Impact factor: 2.736

9.  Pyoderma gangrenosum associated with selective hereditary IgA deficiency.

Authors:  S Bundino; A M Zina
Journal:  Dermatologica       Date:  1984

10.  Treatment of pyoderma gangrenosum with cyclosporine.

Authors:  W L Matis; C N Ellis; C E Griffiths; G S Lazarus
Journal:  Arch Dermatol       Date:  1992-08
View more
  7 in total

1.  [Surgical management of Pyoderma gangrenosum].

Authors:  I Sick; B Trautner; T Ruzicka
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

2.  [Multiple abscesses after a cruise along the Latin American coast].

Authors:  C Reynolds; N Schofer; E Zengin; A W Lohse; S Faiss; S Schmiedel
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

3.  Pyoderma Gangrenosum in the Urologist Clinic.

Authors:  Dina J Ludwig; Hossain Roshani; Martijn G Steffens; Frederik C Moll; Robertus G Teepe
Journal:  Curr Urol       Date:  2016-09-20

4.  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.

Authors:  Anthony D Ormerod; Kim S Thomas; Fiona E Craig; Eleanor Mitchell; Nicola Greenlaw; John Norrie; James M Mason; Shernaz Walton; Graham A Johnston; Hywel C Williams
Journal:  BMJ       Date:  2015-06-12

5.  A case of surgically treated peristomal pyoderma gangrenosum in a patient with rheumatoid arthritis.

Authors:  Masoomeh Khajehnoori; Tim O'Brien
Journal:  J Surg Case Rep       Date:  2016-06-14

6.  Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial.

Authors:  J M Mason; K S Thomas; A D Ormerod; F E Craig; E Mitchell; J Norrie; H C Williams
Journal:  Br J Dermatol       Date:  2017-05-31       Impact factor: 9.302

7.  Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies.

Authors:  Louisa Hinterberger; Cornelia S L Müller; Thomas Vogt; Claudia Pföhler
Journal:  Dermatol Ther (Heidelb)       Date:  2012-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.